UTHR / United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth More Than Justified

United Therapeutics Corporation (NASDAQ:UTHR ) Q3 2023 Earnings Conference Call November 1, 2023 9:00 AM ET Company Participants Dewey Steadman – He more_horizontal

United Therapeutics (UTHR) third-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line. more_horizontal

United Therapeutics (UTHR) came out with quarterly earnings of $5.38 per share, beating the Zacks Consensus Estimate of $4.89 per share. This compares more_horizontal

United Therapeutics Corporation is in a long-term uptrend, reaching a new all-time high, indicating strong demand for the stock. The company has a com more_horizontal

United Therapeutics Corporation (NASDAQ: UTHR) reported strong quarterly results, adding strength to its economic characteristics. The company's finan more_horizontal

United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line. more_horizontal

While the top- and bottom-line numbers for United Therapeutics (UTHR) give a sense of how the business performed in the quarter ended June 2023, it co more_horizontal

United Therapeutics (UTHR) came out with quarterly earnings of $5.24 per share, beating the Zacks Consensus Estimate of $4.41 per share. This compares more_horizontal